![1]()
News
Acute kidney injury linked to later dementia
October 26, 2018
SAN DIEGO – Vascular disease, especially of the small blood vessels, may be a culprit.
![1]()
News
Challenging Dogma: The banana bag
October 26, 2018
The “banana bag” offers too much of some of its ingredients and not enough of others.
![1]()
News
Antipsychotic drugs failed to shorten ICU delirium
October 26, 2018
The mechanisms of brain dysfunction targeted by antipsychotics may not play a major role in delirium.
![1]()
News
VTE risk after gynecologic surgery lower with laparoscopic procedures
October 26, 2018
Laparoscopic and vaginal gynecologic surgery are associated with a lower incidence of postoperative VTE, compared with laparotomy.
![1]()
News
Transition to high-sensitivity troponin T assay helped boost ED discharge rates
October 26, 2018
SAN DIEGO – The study marks the first analysis of its kind in the United States.
![1]()
Article
Daptomycin/fosfomycin: A new standard for MRSA bacteremia?
October 25, 2018
Better survival was seen for MRSA bacteremia at 7 days using the combo vs. monotherapy.
![1]()
News
FDA clears Abbott’s Influenza A & B 2, Strep A 2 assays
October 25, 2018
The Influenza A & B 2 assay can detect and differentiate influenza A and B in 13 minutes, while the Strep A 2 assay detects group A streptococcus bacterial nucleic acid in 6 minutes.
![1]()
News
Length of stay, complications predict readmission for cirrhosis patients
October 25, 2018
PHILADELPHIA – Patients with cirrhosis have a higher risk of hospital readmission if their length of stay is less than 4 days, if they have cirrhosis-related complications, and if they are discharged to an extended-care facility or to home health care, according to a recent presentation at the annual meeting of the American College of Gastroenterology.
![1]()
News
Helping alleviate hospitalist burnout
October 24, 2018
Burnout will diminish when physicians are empowered to be part of the solution.
![1]()
News
FDA approves Xofluza for treatment of influenza
October 24, 2018
The FDA has approved Xofluza for acute uncomplicated influenza in people aged 12 years or older who have been symptomatic for 48 hours or less.
